Medical University Innsbruck, AT
Role and Contribution
The Medical University Innsbruck is involved in WP 5 and 6 in the Mitigate project. Its role is mainly in the translation of preclinical findings on GIST targeting and treatment strategies into a clinical setting. Contributors within MUI will be the Department of Radiology being a leading innovator in performing stereotactic radiofrequency ablation (RFA) using multimodality imaging data (ultrasound, rotational angiography, CT, MR, PET,SPECT) for image fusion and guidance and the Department of Nuclear Medicine with a long lasting experience in the preclinical development and their translation into clinical application of targeted radiopharmaceuticals for PET, SPECT and therapy in particular radiolabeled peptides for oncological applications. Additionally for the planned clinical study the Organizational Unit CTC “Clinical Trial Center” will provide support in planning, performing and evaluating the clinical trial. The contribution of MUI within Mitigate will in a first step be its involvement in preclinical characterisation and pharmaceutical formulation of novel radiolabeled probes targeting TK-resistant GIST tumours. This will then be translated into an exploratory Phase I/II clinical trial with one selected compound in 10 patients with histologically documented TK-resistant GIST tumours using Positronemmission Tomography (PET) for tumour visualisation, characterisation and dosimetry. Stereotactic RFA for treatment of drug resistant/receptor negative metastases will be perfumed based on multimodality imaging data including PET. The trial is planned for a period of 12 month at the end of the MITIGATE project.
Prof. Werner Jaschke is a specialist in Diagnostic and Interventional Radiology. He authored or co-authored more than 250 papers (https://www.researchgate.net/profile/Werner_Jaschke/publications/). He trained at the German Cancer Research Center, University of Heidelberg and the UC San Francisco. Since 1993 he is Head of the Department of Radiology at the Innsbruck Medical University, Austria.
Prof. Dr. Reto Bale is a specialist in Diagnostic and Interventional Radiology. He pioneered the development of stereotactic RFA. He published more than 100 papers.
Prof. Irene Virgolini is specialist in Internal and Nuclear Medicine and has pioneered the application of radiolabeled peptides for targeted diagnosis and therapy. Since 2003 head of the Department of Nuclear Medicine at MUI, more than 15 years of experience in this field make her a world-wide recognised expert in radionuclide therapy treatment and receptor imaging, also exemplified by more than 150 scientific publications in the field. Several 99mTc, 111In and 68Ga labeled peptides have been translated from radiopharmaceutical research to the clinic for PET, SPECT and therapeutic applications under her responsibility.
Univ. Doz. Dr. Clemens Decristoforo is radiopharmacist with the main research area is in the preclinical development of radiometal labelled peptide based radiopharmaceuticals for molecular imaging and targeted radionuclide and more than 100 publications and world-wide research collaborations. He is in the editorial board of the European Journal of Nuclear Medicine and Molecular imaging and other NM-related journals. He is past chairman of the Radiopharmacy committee and member of the expert group on radiopharmaceuticals of the European Pharmacopeia.